Clinical benefit of enzyme replacement therapy in Fabry disease

Kidney International

Volumn 69, Issue 7, 2006, Pages 1216-1221

  Breunig, F ^a   Weidemann, F ^a   Strotmann, J ^a   Knoll, A ^a   Wanner, C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Clinical end points; Enzyme replacement therapy; Fabry disease; Left ventricular hypertrophy; Renal function

Indexed keywords

AGALSIDASE BETA; PENTETATE TECHNETIUM TC 99M;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; FOLLOW UP; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HUMAN; ISOTOPE LABELING; KIDNEY CLEARANCE; KIDNEY FUNCTION; LYSOSOME STORAGE DISEASE; MALE; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME;

ADULT; ALPHA-GALACTOSIDASE; ECHOCARDIOGRAPHY; FABRY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 33645528253     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000208     Document Type: Article

References (23)

1. Desnick RJ, Ioannou YA, Eng CM. Alpha galactosidase deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The Metabolic and Molecular Bases of Inherited Disease, 8th edn, Vol. 3 Mac Graw-Hill: New York, 2001 pp. 3733-3774.
2. Branton MH, Schiffmann R, Kopp JB. Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 2002; 13(Suppl 2): 139-143.
3. Eng CM, Banikazemi M, Gordon RE et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68: 711-722.
4. Schiffmann R, Murray GJ, Treco D et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000; 97: 365-370.
5. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16.
6. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-1946.
7. Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004; 75: 65-74.
8. Schiffmann R, Kopp JB, Austin HA et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-2749.
9. Weidemann F, Breunig F, Beer M et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease. Circulation 2003; 108: 1299-1309.
10. Colombi A, Kostyal A, Bracher R et al. Angiokeratoma corporis diffusum - Fabry's disease. Helv Med Acta 1967; 34: 67-83.
11. Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81: 122-138.
12. Thadani R, Wolf M, West ML et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-259.
13. Ruggenenti P, Perna A, Gherardi G et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 2000; 35: 1155-1165.
14. Beck M, Ricci R, Widmer U et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34: 838-844.
15. Desnick RJ, Brady R, Barranger J et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338-346.
16. von Scheidt W, Eng CM, Fitzmaurice TF et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-399.
17. Nakao S, Kodama C, Takenaka T et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a 'renal variant' phenotype. Kidney Int 2003; 64: 801-807.
18. Pieroni M, Chimenti C, Ricci R et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107: 978-984.
19. Linhart A, Palecek T, Bultas J et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139: 1101-1108.
20. Sachdev B, Takenaka T, Teraguchi H et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-1411.
21. Kampmann C, Baehner F, Whybra C et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40: 1668-1674.
22. Breunig F, Wanner C. Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 2003; 18: 7-9.
23. Breunig F, Weidemann F, Beer M et al. Fabry disease: diagnosis and treatment. Kidney Int 2003; 63(Suppl 84): 181-185.